Ginkgo Bioworks Holdings Inc [NYSE: DNA] gained 1.87% or 0.02 points to close at $1.09 with a heavy trading volume of 11272960 shares. The company report on March 12, 2024 at 7:01 AM that CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago.
The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens..
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC’s Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).
The daily chart for DNA points out that the company has recorded -38.42% loss over the past six months.
If we look at the average trading volume of 22.61M shares, DNA reached to a volume of 11272960 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ginkgo Bioworks Holdings Inc [DNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $1.97 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 3.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 14, 2023. The new note on the price target was released on November 09, 2023, representing the official price target for Ginkgo Bioworks Holdings Inc stock. Previously, the target price had yet another drop from $3 to $1.25, while Goldman kept a Sell rating on DNA stock.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.09, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 8.81. The Price to Book ratio for the last quarter was 1.87, with the Price to Cash per share for the same quarter was set at 0.47.
Trading performance analysis for DNA stock
Ginkgo Bioworks Holdings Inc [DNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by 0.00. With this latest performance, DNA shares dropped by -17.42% in over the last four-week period, additionally sinking by -38.42% over the last 6 months – not to mention a drop of -11.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 40.04, with the RSI for the last a single of trading hit 38.33, and the three-weeks RSI is set at 41.68 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 1.2698, while it was recorded at 1.1080 for the last single week of trading, and 1.6349 for the last 200 days.
Ginkgo Bioworks Holdings Inc [DNA]: A deeper dive into fundamental analysis
Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.11 and a Current Ratio set at 6.11.
Ginkgo Bioworks Holdings Inc [DNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Ginkgo Bioworks Holdings Inc posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 19.50%.
An analysis of Institutional ownership at Ginkgo Bioworks Holdings Inc [DNA]
The top three institutional holders of DNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DNA stock with ownership which is approximately 5.8325%.
